Skip to main content
Top
Published in: Familial Cancer 2/2014

01-06-2014 | Original Article

The MUTYH hotspot mutations p.G396D and p.Y179C do not cause substantial genetic susceptibility to biliary cancer

Authors: M. Casper, M. Acalovschi, F. Lammert, V. Zimmer

Published in: Familial Cancer | Issue 2/2014

Login to get access

Abstract

Inflammation-associated oxidative stress and DNA damage are involved in malignant transformation of cholangiocytes. Defective DNA repair mechanisms may predispose to cholangiocarcinoma (CCA) formation, and an elevated CCA risk for MutY human homologue (MUTYH) germline mutation carriers has been proposed previously. The aim of this study was to re-evaluate the MUTYH hotspot mutations p.Y179C (rs34612342) and p.G396D (rs36053993) as genetic susceptibility factors in a large CCA cohort. The study population consisted of 219 Caucasian CCA patients (66.2 ± 11.9 years, 130 males, 89 females; 43 intrahepatic and 176 extrahepatic tumours; tissue diagnosis in 77.6 %) and 355 healthy controls (61.0 ± 11.0 years; 158 males, 197 females). MUTYH hotspot variants were genotyped using TaqMan assays. Four CCA patients were monoallelic mutation carriers (3 p.G396D; 1 p.Y179C) whereas 6 control subjects were heterozygotes (5 p.G396D; 1 p.Y179C). None of the patients carried a biallelic hotspot mutation. The observed allele frequencies did not differ significantly between cases and controls (p > 0.05) and association tests did not provide evidence for an involvement of p.Y179C (OR 1.6 [95 % CI 0.1–26.0]) or p.G396D (OR 1.0 [95 % CI 0.2–4.1]) in the susceptibility to CCA. Power analysis identified a sufficient power only for large effect sizes (>90 % for OR > 5.8 for p.G396D and OR > 18.5 for p.Y179C). Monoallelic MUTYH hotspot mutations do not act as major genetic susceptibility factors causing a substantial CCA risk in the Caucasian population. Due to the low statistical power for the identification of small effect sizes, much larger studies will be needed to detect such effects of minor clinical significance.
Literature
1.
2.
go back to reference Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D (2006) Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2:407–416CrossRef Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D (2006) Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2:407–416CrossRef
3.
go back to reference Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314PubMedCrossRef Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314PubMedCrossRef
4.
go back to reference Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260PubMedCrossRef Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260PubMedCrossRef
6.
go back to reference Mihalache F, Höblinger A, Grünhage F, Krawczyk M, Gärtner BC, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V (2011) Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther 33:389–394PubMedCrossRef Mihalache F, Höblinger A, Grünhage F, Krawczyk M, Gärtner BC, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V (2011) Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther 33:389–394PubMedCrossRef
7.
go back to reference Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V (2013) Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 45:612–615PubMedCrossRef Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V (2013) Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 45:612–615PubMedCrossRef
10.
go back to reference Jusakul A, Loilome W, Namwat N, Haigh WG, Kuver R, Dechakhamphu S, Sukontawarin P, Pinlaor S, Lee SP, Yongvanit P (2012) Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. Mutat Res 731:48–57PubMedCrossRef Jusakul A, Loilome W, Namwat N, Haigh WG, Kuver R, Dechakhamphu S, Sukontawarin P, Pinlaor S, Lee SP, Yongvanit P (2012) Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. Mutat Res 731:48–57PubMedCrossRef
11.
go back to reference Takao M, Aburatani H, Kobayashi K, Yasui A (1998) Mitochondrial targeting of human DNA glycosylases for repair of oxidative DNA damage. Nucleic Acids Res 26:2917–2922PubMedCentralPubMedCrossRef Takao M, Aburatani H, Kobayashi K, Yasui A (1998) Mitochondrial targeting of human DNA glycosylases for repair of oxidative DNA damage. Nucleic Acids Res 26:2917–2922PubMedCentralPubMedCrossRef
12.
go back to reference Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston A, Williams GT, Hodgkes AK, Davies DR, David SS, Sampson JR, Cheadle JP (2002) Inherited variants of MYH associated with somatic G:C–>T: A mutations in colorectal tumors. Nat Genet 30:227–232PubMedCrossRef Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston A, Williams GT, Hodgkes AK, Davies DR, David SS, Sampson JR, Cheadle JP (2002) Inherited variants of MYH associated with somatic G:C–>T: A mutations in colorectal tumors. Nat Genet 30:227–232PubMedCrossRef
13.
go back to reference Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RKS, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson DM, Thomas HJW, Tomlinson I (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791–799PubMedCrossRef Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RKS, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson DM, Thomas HJW, Tomlinson I (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791–799PubMedCrossRef
14.
go back to reference Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, Broderick P, Gallinger S, Croitoru EM, Jenkins MA, Win AK, Cleary SP, Koessler T, Pharoah PD, Küry S, Bézieau S, Buecher B, Ellis NA, Peterlongo P, Offit K, Aaltonen LA, Enholm S, Lindblom A, Zhou XL, Tomlinson IP, Moreno V, Blanco I, Capellà G, Barnetson R, Porteous ME, Dunlop MG, Farrington SM (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884PubMedCentralPubMedCrossRef Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, Broderick P, Gallinger S, Croitoru EM, Jenkins MA, Win AK, Cleary SP, Koessler T, Pharoah PD, Küry S, Bézieau S, Buecher B, Ellis NA, Peterlongo P, Offit K, Aaltonen LA, Enholm S, Lindblom A, Zhou XL, Tomlinson IP, Moreno V, Blanco I, Capellà G, Barnetson R, Porteous ME, Dunlop MG, Farrington SM (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884PubMedCentralPubMedCrossRef
15.
16.
go back to reference Baudhuin LM, Roberts LR, Enders FT, Swanson RL, Mettler TA, Aderca I, Stadheim LM, Highsmith WE (2006) MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. J Cancer Res Clin Oncol 132:159–162PubMedCrossRef Baudhuin LM, Roberts LR, Enders FT, Swanson RL, Mettler TA, Aderca I, Stadheim LM, Highsmith WE (2006) MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. J Cancer Res Clin Oncol 132:159–162PubMedCrossRef
17.
go back to reference Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, Southey MC, Burnett T, Parfrey PS, Green RC, Le Marchand L, Newcomb PA, Haile RW, Lindor NM, Hopper JL, Gallinger S, Jenkins MA (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256–2262PubMedCentralPubMedCrossRef Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, Southey MC, Burnett T, Parfrey PS, Green RC, Le Marchand L, Newcomb PA, Haile RW, Lindor NM, Hopper JL, Gallinger S, Jenkins MA (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256–2262PubMedCentralPubMedCrossRef
18.
go back to reference You SH, Wang X, Huang S, Wang M, Ji GZ, Xia JR, Fan ZN (2013) MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma. Mol Med Rep 7:347–351PubMed You SH, Wang X, Huang S, Wang M, Ji GZ, Xia JR, Fan ZN (2013) MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma. Mol Med Rep 7:347–351PubMed
19.
go back to reference Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of Gastroenterology (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669PubMedCrossRef Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of Gastroenterology (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669PubMedCrossRef
20.
go back to reference Casper M, Plotz G, Juengling B, Zeuzem S, Lammert F, Raedle J (2012) MUTYH hotspot mutations in unselected colonoscopy patients. Colorectal Dis 14:e238–e244PubMedCrossRef Casper M, Plotz G, Juengling B, Zeuzem S, Lammert F, Raedle J (2012) MUTYH hotspot mutations in unselected colonoscopy patients. Colorectal Dis 14:e238–e244PubMedCrossRef
21.
go back to reference Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, Steinke V, Vasen HF, Propping P, Sampson JR, Hes FJ, Aretz S (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985PubMedCrossRef Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, Steinke V, Vasen HF, Propping P, Sampson JR, Hes FJ, Aretz S (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985PubMedCrossRef
22.
go back to reference Out AA, Tops CM, Nielsen M, Weiss MM, van Minderhout IJ, Fokkema IF, Buisine MP, Claes K, Colas C, Fodde R, Fostira F, Franken PF, Gaustadnes M, Heinimann K, Hodgson SV, Hogervorst FB, Holinski-Feder E, Lagerstedt-Robinson K, Olschwang S, van den Ouweland AM, Redeker EJ, Scott RJ, Vankeirsbilck B, Grønlund RV, Wijnen JT, Wikman FP, Aretz S, Sampson JR, Devilee P, den Dunnen JT, Hes FJ (2010) Leiden open variation database of the MUTYH gene. Hum Mutat 31:1205–1215PubMedCrossRef Out AA, Tops CM, Nielsen M, Weiss MM, van Minderhout IJ, Fokkema IF, Buisine MP, Claes K, Colas C, Fodde R, Fostira F, Franken PF, Gaustadnes M, Heinimann K, Hodgson SV, Hogervorst FB, Holinski-Feder E, Lagerstedt-Robinson K, Olschwang S, van den Ouweland AM, Redeker EJ, Scott RJ, Vankeirsbilck B, Grønlund RV, Wijnen JT, Wikman FP, Aretz S, Sampson JR, Devilee P, den Dunnen JT, Hes FJ (2010) Leiden open variation database of the MUTYH gene. Hum Mutat 31:1205–1215PubMedCrossRef
23.
go back to reference Forsbring M, Vik ES, Dalhus B, Karlsen TH, Bergquist A, Schrumpf E, Bjørås M, Boberg KM, Alseth I (2009) Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis 30:1147–1154PubMedCentralPubMedCrossRef Forsbring M, Vik ES, Dalhus B, Karlsen TH, Bergquist A, Schrumpf E, Bjørås M, Boberg KM, Alseth I (2009) Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis 30:1147–1154PubMedCentralPubMedCrossRef
Metadata
Title
The MUTYH hotspot mutations p.G396D and p.Y179C do not cause substantial genetic susceptibility to biliary cancer
Authors
M. Casper
M. Acalovschi
F. Lammert
V. Zimmer
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9699-2

Other articles of this Issue 2/2014

Familial Cancer 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine